AU2002337277A1 - Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain - Google Patents

Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain

Info

Publication number
AU2002337277A1
AU2002337277A1 AU2002337277A AU2002337277A AU2002337277A1 AU 2002337277 A1 AU2002337277 A1 AU 2002337277A1 AU 2002337277 A AU2002337277 A AU 2002337277A AU 2002337277 A AU2002337277 A AU 2002337277A AU 2002337277 A1 AU2002337277 A1 AU 2002337277A1
Authority
AU
Australia
Prior art keywords
parkinson
brain
compositions
treatment
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002337277A
Other versions
AU2002337277B2 (en
Inventor
Jesus Benavides
Daniel Boccio
Yvette Henin
Odile Piot-Grosjean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0111200A external-priority patent/FR2829028B1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2002337277A1 publication Critical patent/AU2002337277A1/en
Application granted granted Critical
Publication of AU2002337277B2 publication Critical patent/AU2002337277B2/en
Priority to AU2008212039A priority Critical patent/AU2008212039A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002337277A 2001-08-29 2002-08-28 Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain Ceased AU2002337277B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008212039A AU2008212039A1 (en) 2001-08-29 2008-09-05 Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brian, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/11200 2001-08-29
FR0111200A FR2829028B1 (en) 2001-08-29 2001-08-29 COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF DISEASE
PCT/FR2002/002946 WO2003020314A1 (en) 2001-08-29 2002-08-28 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008212039A Division AU2008212039A1 (en) 2001-08-29 2008-09-05 Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brian, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease

Publications (2)

Publication Number Publication Date
AU2002337277A1 true AU2002337277A1 (en) 2003-06-05
AU2002337277B2 AU2002337277B2 (en) 2008-06-05

Family

ID=8866792

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002337277A Ceased AU2002337277B2 (en) 2001-08-29 2002-08-28 Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
AU2008212039A Abandoned AU2008212039A1 (en) 2001-08-29 2008-09-05 Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brian, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008212039A Abandoned AU2008212039A1 (en) 2001-08-29 2008-09-05 Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brian, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease

Country Status (16)

Country Link
US (2) US7217705B2 (en)
EP (2) EP1649849A3 (en)
JP (2) JP2005505551A (en)
AR (1) AR036302A1 (en)
AT (1) ATE328609T1 (en)
AU (2) AU2002337277B2 (en)
CA (1) CA2458348A1 (en)
CY (1) CY1105341T1 (en)
DE (1) DE60212148T2 (en)
DK (1) DK1423145T3 (en)
ES (1) ES2263816T3 (en)
FR (1) FR2829028B1 (en)
IL (2) IL160557A0 (en)
MX (1) MXPA04001645A (en)
PT (1) PT1423145E (en)
WO (1) WO2003020314A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (en) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
DE10041479A1 (en) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition for the administration of N-0923
DE10043321B4 (en) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE10261696A1 (en) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
NZ543451A (en) 2003-06-11 2008-08-29 Merck & Co Inc Substituted 3-alkyl and 3-alkenyl azetidine derivitives
DE10334188B4 (en) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
DE10334187A1 (en) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituted 2-aminotetralins for the treatment of depression
DE10359528A1 (en) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (en) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease
ES2244314B1 (en) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. SUBSTITUTED AZETIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICATIONS.
CA2556565A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted azetidine compounds, their preparation and use as medicaments
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (en) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
TWI392670B (en) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EA016507B1 (en) 2007-01-04 2012-05-30 Прозидион Лимитед Piperidine gpcr agonists
PE20081849A1 (en) 2007-01-04 2009-01-26 Prosidion Ltd PIPERIDIN-4-IL-PROPOXY-BENZAMIDE DERIVATIVES AS GPCR AGONISTS
EA015129B1 (en) 2007-01-04 2011-06-30 Прозидион Лимитед Piperidine gpcr agonists
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
EP2215072B1 (en) * 2007-11-28 2015-09-02 UCB Pharma GmbH Polymorphic form of rotigotine
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
TW201105655A (en) 2009-04-22 2011-02-16 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP3257504B1 (en) 2009-12-22 2024-06-19 UCB Biopharma SRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
US8575363B2 (en) * 2010-10-22 2013-11-05 Janssen Pharmaceutica N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
WO2022245900A2 (en) * 2021-05-21 2022-11-24 Murphy Brian Stuart Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
FR2783246B1 (en) * 1998-09-11 2000-11-17 Aventis Pharma Sa AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM
EP1236476A1 (en) * 1999-12-10 2002-09-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation

Similar Documents

Publication Publication Date Title
AU2002337277A1 (en) Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
IL193325A0 (en) Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
IL160558A0 (en) Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
HUP0402026A3 (en) 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
SI1303272T1 (en) Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease
HUP0103558A3 (en) Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury
MX9801305A (en) Oral fast-dissolving compositions for dopamine agonists.
HUP0302956A3 (en) Thioflavin derivatives for use in diagnosis of alzheimer's disease, process for preparation of compounds and pharmaceutical compositions containing them
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
AU2002319615A1 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
AU2002357267A1 (en) Immune related neuronal receptors and therapeutic uses thereof
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
AU2002341060A1 (en) Composition for treating Parkinson's disease containg a CB1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
AU2003248893A8 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias